Compare Dr. Reddys with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DISHMAN PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DISHMAN PHARMA DR. REDDYS LAB/
DISHMAN PHARMA
 
P/E (TTM) x 22.3 25.1 89.0% View Chart
P/BV x 3.3 3.3 99.9% View Chart
Dividend Yield % 0.7 0.7 106.4%  

Financials

 DR. REDDYS LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
DISHMAN PHARMA
Mar-16
DR. REDDYS LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875374 767.9%   
Low Rs1,888129 1,464.7%   
Sales per share (Unadj.) Rs930.2197.8 470.3%  
Earnings per share (Unadj.) Rs117.421.2 553.7%  
Cash flow per share (Unadj.) Rs185.834.7 535.0%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.8 105.7%  
Book value per share (Unadj.) Rs844.4179.9 469.4%  
Shares outstanding (eoy) m166.0780.69 205.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.3 201.2%   
Avg P/E ratio x20.311.9 170.9%  
P/CF ratio (eoy) x12.87.2 176.9%  
Price / Book Value ratio x2.81.4 201.6%  
Dividend payout %17.09.4 180.6%   
Avg Mkt Cap Rs m395,49620,306 1,947.7%   
No. of employees `00022.00.8 2,649.7%   
Total wages/salary Rs m33,5625,355 626.8%   
Avg. sales/employee Rs Th7,032.819,252.7 36.5%   
Avg. wages/employee Rs Th1,527.96,459.5 23.7%   
Avg. net profit/employee Rs Th887.72,064.1 43.0%   
INCOME DATA
Net Sales Rs m154,48215,961 967.9%  
Other income Rs m3,375265 1,271.7%   
Total revenues Rs m157,85716,226 972.9%   
Gross profit Rs m31,7824,103 774.6%  
Depreciation Rs m11,3481,091 1,040.5%   
Interest Rs m889944 94.1%   
Profit before tax Rs m22,9202,334 982.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m4381 39,818.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858624 618.7%   
Profit after tax Rs m19,5001,711 1,139.6%  
Gross profit margin %20.625.7 80.0%  
Effective tax rate %16.826.7 63.0%   
Net profit margin %12.610.7 117.7%  
BALANCE SHEET DATA
Current assets Rs m111,10111,018 1,008.4%   
Current liabilities Rs m58,9739,517 619.7%   
Net working cap to sales %33.79.4 358.8%  
Current ratio x1.91.2 162.7%  
Inventory Days Days79110 71.8%  
Debtors Days Days9435 270.4%  
Net fixed assets Rs m101,24516,304 621.0%   
Share capital Rs m830161 514.3%   
"Free" reserves Rs m139,40612,907 1,080.1%   
Net worth Rs m140,23614,516 966.1%   
Long term debt Rs m22,0004,189 525.1%   
Total assets Rs m224,65629,805 753.8%  
Interest coverage x26.83.5 771.6%   
Debt to equity ratio x0.20.3 54.4%  
Sales to assets ratio x0.70.5 128.4%   
Return on assets %9.18.9 101.9%  
Return on equity %13.911.8 118.0%  
Return on capital %14.917.5 85.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m88,6734,952 1,790.8%   
Fx outflow Rs m19,104697 2,741.7%   
Net fx Rs m69,5694,255 1,635.1%   
CASH FLOW
From Operations Rs m28,7042,786 1,030.1%  
From Investments Rs m-7,727-1,529 505.4%  
From Financial Activity Rs m-21,326-941 2,266.1%  
Net Cashflow Rs m-314316 -99.2%  

Share Holding

Indian Promoters % 25.5 61.4 41.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 12.7 278.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 22.1 69.2%  
Shareholders   75,885 46,261 164.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS